EL PASO — A study published in JAMA examined loberamisal as a neuroprotective and neuroreparative therapy for stroke. The research found that 70% of patients who received loberamisal had a rank score of 0 to 1, compared to 56% in the placebo group.

TTHealthWatch is a weekly podcast from Texas Tech. Rick Lange is the president of Texas Tech Health El Paso. Elizabeth Tracey is the director of electronic media for Johns Hopkins Medicine in Baltimore.

"Let me start with this new stroke therapy. That's in JAMA," Lange said. "This is a study that looked at loberamisal, which provides both neuroprotective and neuroreparative therapy in individuals that have a stroke."

Lange explained the biological basis for the treatment. Loberamisal is a small-molecule compound that targets the PSD-95 pathway and the GABA pathway. The PSD-95 pathway is responsible for repairing damaged neurons. The GABA pathway is involved with neural repair.

The clinical trial took place in China. The loberamisal study was conducted in China with just under 1,000 patients. Participants received specific interventions following a cerebrovascular event. Patients in the loberamisal study received either routine care or IV loberamisal for 10 days after a stroke.

"This is a study conducted in China where there are just under 1,000 patients and they received either routine care or they received IV loberamisal for 10 days," he said. Researchers assessed patient outcomes using a standardized metric. Functional capacity in the loberamisal study was measured at 90 days using a rank scale of 0 to 6, where 0 indicates no abnormality and 6 indicates death.

"How many of those recovered? That is a rank and scale of 0 to 1. That's a scale of 0 means there's no abnormality at all. And 6, by the way, is death," he said.

"Those that received the loberamisal, 70% of them had a rank and score of 0 to 1 compared to only 56% in the placebo group." The study addressed safety concerns alongside efficacy measures. The loberamisal study reported no serious adverse events.

"What serious adverse events occur? There was really none," he said.

The trial included a subset of patients who underwent standard acute interventions. A small group of individuals in the Chinese loberamisal study received thrombolytic therapy or thrombectomy, and the treatment was equally efficacious in those whose blood flow was restored.

Lange discussed the context of stroke care infrastructure differences between regions. He noted that access to acute centers varies globally.

"In China quite a few, because there are fewer acute stroke centers," he said. "As you know, in the U.S. we have a spoke-and-hub. Individuals that present to outside communities that can't provide thrombectomy or thrombolysis are rapidly shuttled to a center where that's available."

Despite established protocols for clot removal, gaps in eligibility remain. Many patients arrive outside the window for mechanical or chemical intervention.

"We've talked a lot about stroke in the past and its treatment with regard to either dissolving clots and the appropriate time to do that, or using thrombectomy devices to get rid of clots," he said. "But many individuals don't qualify for either thrombolysis or thrombectomy." "Nevertheless, there are some that don't qualify because they present late after a stroke."

Lange described the dual nature of stroke pathology. He distinguished between the initial vascular event and the subsequent cellular response.

"So there are two parts of the stroke. One is occluding the blood flow, and that's what causes a stroke. The other is the neurodegeneration and lack of neural repair that occurs after that," he said.

"Regardless of whether they get thrombolysis therapy, what can we do to facilitate neuronal repair? And that neuroreparative therapy or neuroprotective therapy is what this offers."

He emphasized the importance of rapid restoration of circulation for optimal outcomes. However, he suggested that pharmacological support could benefit a broader population.

"The largest benefit are going to be those in whom you can restore blood flow and restore it quickly before there's irreversible brain damage," he said. "If you have individuals that don't qualify for thrombolysis or thrombectomy, can the administration of this, this IV administration, for 10 days after the stroke help restore full functional capacity measured at 90 days?"

Lange indicated that further research would be necessary to solidify these findings. He agreed with the need for continued investigation into the therapy.

"Elizabeth, I think the answer to that is probably yes. We need additional studies," he said. "So I suspect in the future we're going to both restore blood flow as quickly as possible and in all individuals provide some neuroprotective or neuroreparative therapy."

Why It Matters

The study addresses a gap in care for stroke patients who do not qualify for thrombolysis or thrombectomy. By providing a neuroprotective and neuroreparative option, the therapy offers potential benefits for individuals who present late after a stroke or lack access to acute stroke centers. The results suggest that loberamisal could complement existing treatments by facilitating neuronal repair regardless of whether blood flow is restored immediately.

The findings indicate that early intervention with loberamisal may improve long-term functional capacity. With no serious adverse events reported and equal efficacy in patients who also received thrombolytic therapy or thrombectomy, the treatment presents a viable option for expanding stroke care protocols. Additional studies are needed to confirm these outcomes, but the current data supports the potential for integrating neuroreparative therapy into standard post-stroke management.

What's New

Later reporting detailed the specific biological mechanisms behind the drug's effects. Loberamisal's mechanism involves dual targeting of the PSD-95 pathway (neuronal nitric oxide synthase inhibition) and GABAAR-mediated inhibition, with preclinical evidence suggesting anti-inflammatory and neurogenic effects.